Medicine Questions
Report an Adverse Event
Investors
Contact
North America South America
Asia
Middle East Africa Australia
Europe

Press Releases

March 03, 2006

Gilead Sciences to Present at Two Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--March 3, 2006--Gilead Sciences, Inc. (Nasdaq:GILD):

  • Cowen and Company 26th Annual Healthcare Conference on March 6th
  • 9th Annual Lehman Brothers Global Healthcare Conference on March 9th
  • Webcasts Available Through Gilead Corporate Website

Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its corporate presentation will be webcast at two upcoming investor conferences: the Cowen and Company 26th Annual Healthcare Conference, in Boston, MA, and the 9th Annual Lehman Brothers Global Healthcare Conference, in Miami, Florida. These webcasts may be accessed via the company's corporate website at www.gilead.com.

John Martin, PhD, Gilead's President and Chief Executive Officer, will provide an overview of the company and an update on key business milestones at the Cowen conference on Monday, March 6th at 1:30 p.m. Eastern Time.

John Milligan, PhD, Gilead's Executive Vice President and Chief Financial Officer, will provide an overview of the company and an update on key business milestones at the Lehman conference on Thursday, March 9th at 2:00 p.m. Eastern Time.

To access the live webcasts via the internet log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to each live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715
SOURCE: Gilead Sciences, Inc.